

## DAFTAR PUSTAKA

- Abrams, J., 2005. Chronic Stable Angina. *New England Journal of Medicine*.
- Anand, S.S., Islam, S., Rosengren, A., Franzosi, M.G., Steyn, K., Yusufali, A.H., et.al., 2008. Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. *European Heart Journal*.
- Austin, M. B., 1988. Low-density lipoprotein subclass patterns and risk of myocardial infarction. *JAMA*, 260(13):1917-21.
- Bair, T.L., Muhlestein, J.B., May, H.T., Meredith, K.G., Horne, B.D., Pearson, R.R., et.al., 2007. Surgical Revascularization Is Associated With Improved Long-Term Outcomes Compared With Percutaneous Stenting in Most Subgroups of Patients With Multivessel Coronary Artery Disease. *Circ AHA Journal*, 116:1-226-1-231.
- Barron HV, et.al., 2000. Association Between White Blood Cell Count, Epicardial Blood Flow, Myocardial Perfusion, and Clinical Outcomes in the Setting of Acute Myocardial Infarction. *American Heart Association Journal*, 102: 2329-2334.
- Beck, R., 2014. *Advanced Emergency Medical Technician Transition Manual*. Burlington: Jones & Bartlett Learning.
- Ben-Dor, I, Battler, A., 2007. Treatment of stable angina. *British Medical Journal*, 93(7):868-874.
- Clayton, T.C., Lubsen, J, Pocock, S.J., Zoltán Vokó, Bridger-Anne Kirwan, Fox, K.A.A, Poole-Wilson, P.A., 2005. Risk Score for Predicting death, myocardial, and stroke in patients with stable angina, based on a large randomized trial cohort of patients. *British Medical Journal*, 331(7521): 869.
- Creager, M.A., Lüscher, T.F., Cosentino, F., Beckman, J.A., 2003. Diabetes and Vascular Disease Pathophysiology, Clinical Consequences, and Medical Therapy: Part I. *Circ AHA Journal*, 108:1527-1532.

- Dagres, N. H., 2013. Risk stratification after myocardial infarction: is left ventricular ejection fraction enough to prevent sudden cardiac death? *Eur Heart Journal*, 34(26):1964-71.
- Daly, C. A., et al., 2006. Predicting prognosis in stable angina—results from the Euro heart survey of stable angina: prospective observational study. *British Medical Journal*, 332(7536): 262-267.
- Danchin, N., Cucherat, M., Thuillez, C., et. al.. 2006. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction. An overview of long-term randomized controlled trials. *Arch Intern Med* 2006; 166: 787-796.
- Delima, L. M., 2009. Prevalensi dan Faktor Determinan Penyakit Jantung. *Puslitbang Biomedis dan Farmasi*, 142 - 159.
- Elliott, H.L., Meredith, P.A., 2011. Preferential benefits of nifedipine GITS in systolic hypertension and in combination with RAS blockade: further analysis of the 'ACTION' database in patients with angina. *Journal of Human Hypertension*, 25, 63-70.
- Ferrari, R., Guardigli, G., Ceconi, C., 2010. Secondary Prevention of CAD with ACE inhibitors: a struggle between life and death of the endothelium. *Cardiovasc Drugs Ther*, 24(4): 331-9.
- Hankey, GJ., Jamrozik, K., Broadhurst, RJ., Forbes, S., Burvill, PW., Anderson, CS., et.al., 2000. Five-year survival after first-ever stroke and related prognostic factors in the Perth Community Stroke Study. *Stroke*, 31(9):2080-6.
- Hjemdahl, P., Eriksson, S.V., Held, C., Forslund, L., Näsman, P., and Rehnqvist N., 2006. Favourable long term prognosis in stable angina pectoris: an extended follow up of the angina prognosis study in Stockholm (APSIS). *Heart*, 92(2): 177-182.
- Kurz R.B., 1991. [Anti-angina therapy of coronary heart disease. Mono- or combination treatment], 80(5):305-16.

- Last, A.R., Ference, J.D., Falleroni, J., 2011. Pharmacologic Treatment of Hyperlipidemia. *American Academy of Family Physicians*, 1;84(5):551-558.
- Lilly, L., 2011. *Pathophysiology of Heart Disease*. Philadelphia: Lippincott Williams & Wilkins.
- Lubsen, J., Wagener, G., Kirwan, B.A., Brouwer, S.D., Poole-Wilson, P.A., 2005. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. *J Hypertens*, 23:641-648.
- McCrum-Gardner, Evie, 2010. Sample size and power calculations made simple, research methodology series. *International Journal of Therapy and Rehabilitation*, Vol 17, No 1.
- Medlineplus, 2015. *Stroke*. Rockville Pike, Bethesda: National Institute of Neurological Disorders and Stroke.
- Miller, M., 2009. Dyslipidemia and cardiovascular risk: the importance of early prevention. *Oxford University Press*, 657-667.
- Nielson, C., Lange, T., dan Hadjokas, N., 2006. Blood Glucose and Coronary Artery Disease in Nondiabetic Patient. *American Diabetes Association*.
- Nordestgaard, B.B.H., 2007. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. *JAMA*, 298(3):299-308.
- Pham, T. C., 2010. *Analysis of Major Adverse Cardiac Events with Entropy-Based Complexity*. *Intelligent and Soft Computing*, 261-272.
- Poole-Wilson, P.A., Lubsen, J., Kirwan B.A., Dalen, F.J.V., Wagener, G., Danchin, N., 2004. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. *Lancet*, 364:849-57.

- Poole-Wilson, P.A., Zolota'n Voko', Kirwan, B.A., Brouwer, S.D., Dunselman, P.H.J.M., dan Lubsen, J., 2007. Clinical course of isolated stable angina due to coronary heart disease. *European Heart Journal*.
- Sastroasmoro, S. e., 2011. *Dasar-Dasar Metodologi Penelitian Klinis* (4 ed.). Jakarta: Sagung Seto.
- Schwartz PJ, W. S., 2015. QT Interval Prolongation as Predictor of Sudden Death. *American Heart Association Journal*, 1074-77.
- Slim, I.B., 2013. Cardiovascular risk in type 1 diabetes mellitus. *Indian J Endocrinol Metab*. 17(Suppl1): S7-S13.
- Sutton, G.C., Otterstad, J.E., Kirwan, B.A., Vokó, Z., Brouwer, S.D., Lubsen, J., Poole-Wilson, P.A., 2006. The development of heart failure in patients with stable angina pectoris. *The European Journal of Heart Failure*.
- Thune JJ, et. al., 2011. Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction. *Eur J Heart Fail*, 13(2):148-53.
- Vanasse, A., Courteau, J., Niyonsenga, T., 2006. Revascularization and cardioprotective drug treatment in myocardial infarction patients: how do they impact on patients' survival when delivered as usual care. *BMC Cardiovasc Disord*, 6: 21.
- Voight, B. e., 2012. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. *Lancet*, 380(9841):572-80.
- WHO, (2015). *Cardiovascular Disease*. WHO.
- World Heart Federation, 2015. Cardiovascular disease risk factors. *World Heart Federation*.  
<http://www.mayoclinic.org/>. (n.d.). Retrieved Maret 15, 2014